Literature DB >> 27497296

Oncolytic herpes simplex virus interactions with the host immune system.

Dipongkor Saha1, Hiroaki Wakimoto1, Samuel D Rabkin2.   

Abstract

Oncolytic viruses (OVs), like oncolytic herpes simplex virus (oHSV), are genetically engineered to selectively replicate in and kill cancer cells, while sparing normal cells. Initial OV infection, cell death, and subsequent OV propagation within the tumor microenvironment leads to a cascade of host responses (innate and adaptive), reflective of natural anti-viral immune responses. These host-virus interactions are critical to the balance between OV activities, anti-viral immune responses limiting OV, and induction of anti-tumor immunity. The host response against oHSV is complex, multifaceted, and modulated by the tumor microenvironment and immunosuppression. As a successful pathogen, HSV has multiple mechanisms to evade such host responses. In this review, we will discuss these mechanisms and HSV evasion, and how they impact oHSV therapy. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27497296      PMCID: PMC5138121          DOI: 10.1016/j.coviro.2016.07.007

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  89 in total

1.  Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5.

Authors:  Junji Xing; Shuai Wang; Rongtuan Lin; Karen L Mossman; Chunfu Zheng
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells.

Authors:  Ayuko Sato; Melissa M Linehan; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-03       Impact factor: 11.205

Review 3.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

4.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Novel antiviral activity of chemokines.

Authors:  Takashi Nakayama; Jumi Shirane; Kunio Hieshima; Michiko Shibano; Masayasu Watanabe; Zhe Jin; Daisuke Nagakubo; Takuya Saito; Yoshikazu Shimomura; Osamu Yoshie
Journal:  Virology       Date:  2006-04-17       Impact factor: 3.616

6.  The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNFα- and FasL-induced apoptosis by interacting with caspase-8.

Authors:  Florent Dufour; A Marie-Josée Sasseville; Stéphane Chabaud; Bernard Massie; Richard M Siegel; Yves Langelier
Journal:  Apoptosis       Date:  2011-03       Impact factor: 4.677

7.  Interleukin-18 protects mice against acute herpes simplex virus type 1 infection.

Authors:  N Fujioka; R Akazawa; K Ohashi; M Fujii; M Ikeda; M Kurimoto
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  HSV-1 ICP27 suppresses NF-kappaB activity by stabilizing IkappaBalpha.

Authors:  Jin Chul Kim; Soo Yun Lee; Sang Young Kim; Jeong Ki Kim; Hye Jin Kim; Hee Min Lee; Mi Sun Choi; Jung Sun Min; Mi Jee Kim; Hyang Soon Choi; Jeong Keun Ahn
Journal:  FEBS Lett       Date:  2008-06-06       Impact factor: 4.124

9.  STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.

Authors:  Joshua D Jackson; James M Markert; Li Li; Steven L Carroll; Kevin A Cassady
Journal:  Mol Cancer Res       Date:  2016-02-16       Impact factor: 5.852

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more
  20 in total

1.  Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.

Authors:  Dipongkor Saha; Samuel D Rabkin
Journal:  Methods Mol Biol       Date:  2020

2.  Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Authors:  Dipongkor Saha; Hiroaki Wakimoto; Cole W Peters; Slawomir J Antoszczyk; Samuel D Rabkin; Robert L Martuza
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

3.  Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.

Authors:  Ji Young Yoo; Jessica Swanner; Yoshihiro Otani; Mitra Nair; Flora Park; Yeshavanth Banasavadi-Siddegowda; Joseph Liu; Alena Cristina Jaime-Ramirez; Bangxing Hong; Feng Geng; Deliang Guo; Darlene Bystry; Mitch Phelphs; Haroon Quadri; Tae Jin Lee; Balveen Kaur
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

4.  Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.

Authors:  Dipongkor Saha; Robert L Martuza; Samuel D Rabkin
Journal:  Immunotherapy       Date:  2018-07       Impact factor: 4.196

5.  Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.

Authors:  Juri Kiyokawa; Yoichiro Kawamura; Shanawaz M Ghouse; Simge Acar; Erinç Barçın; Jordi Martínez-Quintanilla; Robert L Martuza; Ramon Alemany; Samuel D Rabkin; Khalid Shah; Hiroaki Wakimoto
Journal:  Clin Cancer Res       Date:  2020-11-30       Impact factor: 13.801

Review 6.  Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.

Authors:  Jie Yin; James M Markert; Jianmei W Leavenworth
Journal:  Front Oncol       Date:  2017-06-26       Impact factor: 6.244

7.  Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.

Authors:  Hannah M Burgess; Aldo Pourchet; Cristina H Hajdu; Luis Chiriboga; Alan B Frey; Ian Mohr
Journal:  Mol Ther Oncolytics       Date:  2018-01-31       Impact factor: 7.200

8.  TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.

Authors:  Brian Hutzen; Chun-Yu Chen; Pin-Yi Wang; Les Sprague; Hayley M Swain; Julia Love; Joe Conner; Louis Boon; Timothy P Cripe
Journal:  Mol Ther Oncolytics       Date:  2017-09-08       Impact factor: 7.200

Review 9.  Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.

Authors:  Roger Li; Jingsong Zhang; Scott M Gilbert; José Conejo-Garcia; James J Mulé
Journal:  Nat Rev Urol       Date:  2021-06-28       Impact factor: 14.432

10.  Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.

Authors:  Dipongkor Saha; Robert L Martuza; Samuel D Rabkin
Journal:  Oncoscience       Date:  2017-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.